NCT05244226

Brief Summary

The purpose of this study is to compare the use of short acting opioids (fentanyl/hydromorphone) with long acting opioids (methadone) for pain control following tonsillectomy surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
66

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Apr 2022

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 8, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 17, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

April 8, 2022

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 10, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 10, 2023

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

October 17, 2024

Completed
Last Updated

October 17, 2024

Status Verified

October 1, 2024

Enrollment Period

1.1 years

First QC Date

February 8, 2022

Results QC Date

March 20, 2024

Last Update Submit

October 16, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Total Amount of Opioid Medications Administered

    Postoperative opioid medication expressed in oral morphine equivalents (OME) per kilogram

    Up to 7 days post surgery

Secondary Outcomes (5)

  • Percentage of Scores on the Parent Post Operative Pain Measure (PPPM) That Indicate Clinically Significant Pain

    Up to 7 days post surgery

  • NIH PROMIS (Patient-Reported Outcomes Measurement Information System) Parent Proxy Report Scale

    Up to 7 days post surgery

  • Evaluation of Participant's Pain as Measured by Numeric Pain Rating Scale

    Up to 7 days post surgery

  • Doses of Prescription Opioid Used Following Hospital Discharge

    Up to 7 days post surgery

  • Opioid Administration in the PACU (Post-anesthesia Care Unit)

    Up to 6 hours post surgery

Study Arms (2)

Short acting opioids: Fentanyl, Hydromorphone

ACTIVE COMPARATOR
Drug: Fentanyl/Hydromorphone

Long Acting Opioid: Methadone

ACTIVE COMPARATOR
Drug: Methadone

Interventions

Per routine care

Short acting opioids: Fentanyl, Hydromorphone

Initial dosing 0.1mg/kg, potential to escalate to 0.15mg/kg following interim analysis

Long Acting Opioid: Methadone

Eligibility Criteria

Age3 Years - 17 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Children ages 3 to 17 years old
  • Presenting for elective tonsillectomy +/- adenoidectomy
  • Provide informed consent / assent (as appropriate)

You may not qualify if:

  • History of liver or kidney disease
  • Females with positive pregnancy test
  • Severe sleep apnea (Sleep study with Apnea Hypopnea Index (AHI) \> 10)
  • Consistent daily opioid use for chronic pain ( \>3 months)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duke University School of Medicine

Durham, North Carolina, 27710, United States

Location

Related Publications (1)

  • Einhorn LM, Hoang J, La JO, Kharasch ED. Single-dose Intraoperative Methadone for Pain Management in Pediatric Tonsillectomy: A Randomized Double-blind Clinical Trial. Anesthesiology. 2024 Sep 1;141(3):463-474. doi: 10.1097/ALN.0000000000005031.

MeSH Terms

Conditions

Sleep Apnea, ObstructiveTonsillitisPain, Procedural

Interventions

FentanylHydromorphoneMethadone

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesPharyngitisRespiratory Tract InfectionsInfectionsPharyngeal DiseasesStomatognathic DiseasesOtorhinolaryngologic DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsKetonesOrganic Chemicals

Results Point of Contact

Title
Lisa Einhorn, MD
Organization
Duke University

Study Officials

  • Lisa M Einhorn, MD

    Duke University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 8, 2022

First Posted

February 17, 2022

Study Start

April 8, 2022

Primary Completion

May 10, 2023

Study Completion

May 10, 2023

Last Updated

October 17, 2024

Results First Posted

October 17, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations